• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BCHE Gene Record

  • Summary
  • Interactions
  • Claims
  • BCHE 590 Druggable GenomeDrug Resistance

    Alternate Names:

    590
    BUTYRYLCHOLINESTERASE
    BCHE
    CHE1
    CHE2
    E1
    177400
    983
    ENSG00000114200
    OTTHUMG00000158131
    CHOLINESTERASE
    BUTYRYLCHOLINE ESTERASE
    PSEUDOCHOLINESTERASE
    CHOLINE ESTERASE II
    P06276
    ACYLCHOLINE ACYLHYDROLASE
    CHLE_HUMAN
    CHOLINESTERASE PRECURSOR (EC 3.1.1.8) (ACYLCHOLINE ACYLHYDROLASE) (CHOLINE ESTERASE II) (BUTYRYLCHOLINE ESTERASE) (PSEUDOCHOLINESTERASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P06276]
    BE0002180
    2471
    PA25294
    T99799
    NM_000055
    NP_000046

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:3.1.1.8
    Target Main Class Enzymes
    Target Subclass 3.1.1.8
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Acc IPR002018
    Interpro Type Domain
    Interpro Name Carboxylesterase, type B
    Interpro Short Name CarbesteraseB
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name Acetylcholine turnover
    GuideToPharmacology Gene Category ID 765
    GuideToPharmacology Gene Category Name Hydrolases
    GuideToPharmacology Gene Category ID 799
    (12 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    DRUGGABLE GENOME
    ENZYME

    Publications:

    Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease., Cochrane Database Syst Rev
    Gottwald et al., 1999, Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status., Expert Opin Investig Drugs
    Naik et al., 2009, Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice., J Pharm Pharm Sci
    Scacchi R et al., 2009, Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine., Am J Med Genet B Neuropsychiatr Genet
    Lalli et al., 2008, Rivastigmine in Parkinson's disease dementia., Expert Rev Neurother
    Han HJ et al., 2015, Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease., Eur Neurol
    Greig et al., 2002, Butyrylcholinesterase: an important new target in Alzheimer's disease therapy., Int Psychogeriatr
    Birks et al., 2009, Rivastigmine for Alzheimer's disease., Cochrane Database Syst Rev
    Stahl, 2000, The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different., J Clin Psychiatry
    Bassil et al., 2009, Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease., CNS Drugs
    Onor et al., 2007, Rivastigmine in the treatment of Alzheimer's disease: an update., Clin Interv Aging
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Smith, 2009, Treatment of Alzheimer's disease in the long-term-care setting., Am J Health Syst Pharm
    Blesa R et al., 2006, Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease., Pharmacogenet Genomics
    O'Brien KK et al., 2003, Regulation of attention and response to therapy in dementia by butyrylcholinesterase., Pharmacogenetics
    Farlow, 2003, Update on rivastigmine., Neurologist
    Kamata et al., 2001, Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen., Neurotoxicology
    Acey et al., 2002, A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity?, Biochem. Biophys. Res. Commun.
    Pittel et al., 1992, Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes., Brain Res.
    Miller et al., 1991, Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection., Anal. Biochem.
    Kelly et al., 1990, The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles., Br. J. Pharmacol.
    Garcia DF et al., 2011, Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine., Genet Mol Biol
    Gätke MR et al., 2007, Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia., Pharmacogenet Genomics
    Delacour H et al., 2014, Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium., PLoS One
    Mollerup HM et al., 2011, Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy., Acta Anaesthesiol Scand
    Zavorotnyy M et al., 2011, Prolonged apnea during electroconvulsive therapy in monozygotic twins: case reports., Ann Gen Psychiatry
    McGuire MC et al., 1989, Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase., Proc Natl Acad Sci U S A
    Alvarellos ML et al., 2015, PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics., Pharmacogenet Genomics
    Nogueira CP et al., 1992, Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase., Am J Hum Genet
    Lando G et al., 2003, Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study., Pharmacogenetics
    Parnas ML et al., 2011, Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting., Am J Clin Pathol
    Yen T et al., 2003, Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population., Clin Chem
    Levano S et al., 2005, Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine., Anesthesiology
    Janas et al., 2005, The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats., Life Sci.
    Meiniel, 1981, Neuromuscular blocking agents and axial teratogenesis in the avian embryo. Can axial morphogenetic disorders by explained by pharmacological action upon muscle tissue?, Teratology
    Gum et al., 1993, Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma., Am. J. Vet. Res.
    Negrão AB et al., 2013, Butyrylcholinesterase genetic variants: association with cocaine dependence and related phenotypes., PLoS One
    Kao et al., 1996, The reversal of profound mivacurium-induced neuromuscular blockade., Can J Anaesth
    Wichmann S et al., 2016, Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene., Pharmacogenet Genomics
    Saxena et al., 1997, Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase., Biochemistry
    Harel et al., 1992, Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis., Proc. Natl. Acad. Sci. U.S.A.
    Servatius et al., 2000, Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats., Physiol. Behav.
    Somani et al., Interactive and delayed effects of pyridostigmine and physical stress on biochemical and histological changes in peripheral tissues of mice., J Appl Toxicol
    Abou-Donia et al., 1996, Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos., Fundam Appl Toxicol
    Guemei et al., 2001, Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan., Cancer Chemother. Pharmacol.
    Ahmed et al., 2006, Inhibition of two different cholinesterases by tacrine., Chem. Biol. Interact.
    Marco et al., 2003, Recent developments in the synthesis of acetylcholinesterase inhibitors., Mini Rev Med Chem
    Wang et al., 1998, Anticholinesterase effects of huperzine A, E2020, and tacrine in rats., Zhongguo Yao Li Xue Bao
    Krustev et al., 2006, Calcium-independent tacrine-induced relaxation of rat gastric corpus smooth muscles., Can. J. Physiol. Pharmacol.
    Stoytcheva et al., 2006, Electrochemical sensor based on Arthrobacter globiformis for cholinesterase activity determination., Biosens Bioelectron
    Amenta et al., 2006, Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission., Mech. Ageing Dev.
    Calaf et al., 2007, Gene expression signature of parathion-transformed human breast epithelial cells., Int. J. Mol. Med.
    Lurie et al., 2007, Reduced pseudocholinesterase activity in patients with HELLP syndrome., Reprod Sci
    Hsieh et al., 2007, Choline biosensor constructed with chitinous membrane from soldier crab and its application in measuring cholinesterase inhibitory activities., J Pharm Biomed Anal
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Ramos et al., 2006, Influence of malathion on acetylcholinesterase activity in rats submitted to a forced swimming test., Neurotox Res
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    da Silva et al., 2006, Lactational exposure to malathion inhibits brain acetylcholinesterase in mice., Neurotoxicology
    Ahmed et al., 2007, Malathion, carbofuran and paraquat inhibit Bungarus sindanus (krait) venom acetylcholinesterase and human serum butyrylcholinesterase in vitro., Ecotoxicology
    Henderson et al., 1989, Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle., J. Pharmacol. Exp. Ther.
    Debord et al., 2002, Inhibition of butyrylcholinesterase by phenothiazine derivatives., J Enzyme Inhib Med Chem
    Hahn et al., 1994, Effects of the synthetic glucocorticoid triamcinolone acetonide on vasoactive hydrolases of the human placenta in vitro., Placenta
    Khan et al., 2001, Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of butyrylcholinesterase., Hum Exp Toxicol
    Pohanka et al., 2009, In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048., J Enzyme Inhib Med Chem
    Nordberg A et al., 2013, A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease., Prim Care Companion CNS Disord
    Heydorn, 1997, Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease., Expert Opin Investig Drugs
    De Beaumont L et al., 2016, Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects., J Alzheimers Dis
    Bullock et al., 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period., Curr Med Res Opin
    Sokolow S et al., 2017, Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment., J Alzheimers Dis
    Liston DR et al., 2004, Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease., Eur J Pharmacol
    Ogura H et al., 2000, Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro., Methods Find Exp Clin Pharmacol
    Seltzer B, 2005, Donepezil: a review., Expert Opin Drug Metab Toxicol
    Schuh, 1976, Interaction of hexafluorenium with human plasma cholinesterase in comparison with hexamethonium., Naunyn Schmiedebergs Arch. Pharmacol.
    Nakamura et al., 1993, Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride., Ophthalmic Res.
    Bag S et al., 2013, Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease., Bioorg Med Chem Lett
    Lilienfeld, 2002, Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease., CNS Drug Rev
    Giacobini, 2001, Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?, Drugs Aging
    Svoboda et al., 2006, Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues., Neuro Endocrinol. Lett.
    Wilkinson, 2001, Galantamine: a new treatment for Alzheimer's disease., Expert Rev Neurother
    Galenko-Yaroshevskii et al., 2003, Pharmacokinetics and pharmacodynamics of a new local anesthetic agent., Bull. Exp. Biol. Med.
    Tacal O et al., 2010, Methamidophos, dichlorvos, O-methoate and diazinon pesticides used in Turkey make a covalent bond with butyrylcholinesterase detected by mass spectrometry., J Appl Toxicol
    Kohrs R et al., 1998, Ketamine: teaching an old drug new tricks., Anesth Analg
    Bourne Y et al., 2006, Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding., J Biol Chem
  • RIVASTIGMINE   BCHE

    Interaction Score: 8.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    16437532 11139819 19470293 18780301 18671661 25376930 12636181 19370562 11078030 19374459 18044073 11752352 19420308 17047484 12668920 14587496


    Sources:
    TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • CHEMBL215344   BCHE

    Interaction Score: 6.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235 17139284 17016423


    Sources:
    DrugBank

  • CHEMBL139908   BCHE

    Interaction Score: 4.61

    Interaction Types & Directionality:
    substrate

    Interaction Info:

    PMIDs:
    16837465 10592235


    Sources:
    DrugBank

  • HEXAFLURONIUM   BCHE

    Interaction Score: 4.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    11752352 948350


    Sources:
    DrugBank

  • ISOFLUROPHATE   BCHE

    Interaction Score: 4.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11405252 12459190 1511344 1776688 2361169


    Sources:
    TEND TdgClinicalTrial DrugBank

  • SUXAMETHONIUM   BCHE

    Interaction Score: 2.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21637541 18075469 25054547 21029050 22053728 2915989 26398623 1415224 12724618 21228368 12881446 15731589


    Sources:
    FDA PharmGKB

  • PRALIDOXIME   BCHE

    Interaction Score: 2.3

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    11393267 18825528


    Sources:
    DrugBank

  • ECHOTHIOPHATE   BCHE

    Interaction Score: 2.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    2481033 11752352


    Sources:
    DrugBank

  • EDROPHONIUM   BCHE

    Interaction Score: 2.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    9398183 1438284


    Sources:
    DrugBank

  • DEMECARIUM   BCHE

    Interaction Score: 2.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    7196602 8430939


    Sources:
    DrugBank

  • GALANTAMINE   BCHE

    Interaction Score: 2.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23540646 12177686 11888344 17159811 19811027


    Sources:
    DTC DrugBank

  • MIVACURIUM   BCHE

    Interaction Score: 1.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8922768 27031121


    Sources:
    FDA PharmGKB DrugBank

  • MALATHION   BCHE

    Interaction Score: 1.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    10592235 17139284 16782587 17016423 16716398 17364237


    Sources:
    DrugBank

  • VOLANESORSEN   BCHE

    Interaction Score: 1.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DONEPEZIL   BCHE

    Interaction Score: 1.54

    Interaction Types & Directionality:
    inducer (activating)

    Interaction Info:

    PMIDs:
    23930233 18780301 15989517 27567841 16083542 27911294 17047484 14751402 11256231 16863459


    Sources:
    NCI PharmGKB DrugBank

  • MEPTAZINOL   BCHE

    Interaction Score: 1.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHOLINE SALICYLATE   BCHE

    Interaction Score: 1.32

    Interaction Types & Directionality:
    product of

    Interaction Info:

    PMIDs:
    16376069 16297435 17390078 17636231 17329059


    Sources:
    DrugBank

  • TACRINE   BCHE

    Interaction Score: 1.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    16860785 12871155 10375753 17218977


    Sources:
    DrugBank GuideToPharmacology

  • CHOLINE   BCHE

    Interaction Score: 1.15

    Interaction Types & Directionality:
    product of

    Interaction Info:

    PMIDs:
    16376069 16297435 17390078 17636231 17329059


    Sources:
    DrugBank

  • PYRIDOSTIGMINE   BCHE

    Interaction Score: 0.96

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Inhibition of human plasma BCHE activity by a modified Ellman assay.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    10869589 10942908 8954750


    Sources:
    DrugBank GuideToPharmacology

  • RIVASTIGMINE TARTRATE   BCHE

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cholinesterases; ACHE & BCHE inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TACRINE HYDROCHLORIDE   BCHE

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cholinesterases; ACHE & BCHE inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BAMBUTEROL   BCHE

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • EPTASTIGMINE   BCHE

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DICHLORVOS   BCHE

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20229498


    Sources:
    DrugBank

  • DIPIVEFRIN   BCHE

    Interaction Score: 0.51

    Interaction Types & Directionality:
    potentiator
    substrate

    Interaction Info:

    PMIDs:
    8446367


    Sources:
    DrugBank

  • PHENSERINE   BCHE

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    15620572


    Sources:
    DrugBank

  • PHYSOSTIGMINE   BCHE

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • BUPIVACAINE   BCHE

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14631501


    Sources:
    NCI

  • PHENOTHIAZINE   BCHE

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12443046


    Sources:
    NCI

  • KETAMINE   BCHE

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    9806706


    Sources:
    DrugBank

  • TRIAMCINOLONE   BCHE

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7937594


    Sources:
    NCI

  • BUTANOIC ACID   BCHE

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • CHEMBL1234276   BCHE

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • COCAINE   BCHE

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24312228


    Sources:
    PharmGKB

  • IRINOTECAN   BCHE

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11345644


    Sources:
    NCI PharmGKB

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   BCHE

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000114200

    • Version: 101_38

    Alternate Names:
    BCHE Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000114200

    • Version: 26-July-2011

    Alternate Names:
    CHOLINESTERASE PRECURSOR (EC 3.1.1.8) (ACYLCHOLINE ACYLHYDROLASE) (CHOLINE ESTERASE II) (BUTYRYLCHOLINE ESTERASE) (PSEUDOCHOLINESTERASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P06276] Description
    ENSG00000114200 Ensembl Gene Id
    BCHE Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P06276

    • Version: 01-August-2011

    Alternate Names:
    590 Entrez Gene Id
    ENSG00000114200 Ensembl Gene Id
    P06276 Uniprot Accession

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 3.1.1.8

    Publications:

  • HopkinsGroom: P06276

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000114200 Ensembl Gene Id
    CHLE_HUMAN Uniprot Id
    590 Entrez Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P06276

    • Version: January-2014

    Alternate Names:
    BCHE Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.1.1.8

    Publications:

  • GuideToPharmacology: 590

    • Version: 29-September-2020

    Alternate Names:
    983 HUGO Gene ID
    983 HUGO Gene Symbol
    butyrylcholinesterase HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Acetylcholine turnover
    GuideToPharmacology Gene Category ID 765
    GuideToPharmacology Gene Category Name Hydrolases

    Gene Categories:
    ENZYME

    Publications:

  • PharmGKB: BCHE

    • Version: 18-August-2020

    Alternate Names:
    PA25294 PharmGKB ID

    Gene Info:

    Publications:
    Negrão AB et al., 2013, Butyrylcholinesterase genetic variants: association with cocaine dependence and related phenotypes., PLoS One
    Scacchi R et al., 2009, Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine., Am J Med Genet B Neuropsychiatr Genet
    De Beaumont L et al., 2016, Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects., J Alzheimers Dis

  • DrugBank: BE0002180

    • Version: 5.1.7

    Alternate Names:
    BCHE DrugBank Gene Name
    P06276 UniProt Accession
    590 Entrez Gene Id

    Gene Info:

    Publications:
    Stoytcheva et al., 2006, Electrochemical sensor based on Arthrobacter globiformis for cholinesterase activity determination., Biosens Bioelectron
    Amenta et al., 2006, Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission., Mech. Ageing Dev.
    Calaf et al., 2007, Gene expression signature of parathion-transformed human breast epithelial cells., Int. J. Mol. Med.

  • NCI: BCHE

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Debord et al., 2002, Inhibition of butyrylcholinesterase by phenothiazine derivatives., J Enzyme Inhib Med Chem
    Galenko-Yaroshevskii et al., 2003, Pharmacokinetics and pharmacodynamics of a new local anesthetic agent., Bull. Exp. Biol. Med.
    Galli et al., 1996, Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences., J. Pharm. Pharmacol.

  • DTC: BCHE

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Bag S et al., 2013, Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease., Bioorg Med Chem Lett

  • HingoraniCasas: ENSG00000114200

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000114200 Gene Symbol
    BCHE Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: CHE1

    • Version: chembl_23

    Alternate Names:
    CHE1 GENE_SYMBOL
    BCHE GENE_SYMBOL
    Cholinesterase UNIPROT

    Gene Info:

    Publications:

  • Pharos: BCHE

    • Version: 03-September-2020

    Alternate Names:
    Cholinesterase Gene Name
    P06276 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • GO: BCHE

    • Version: 05-September-2020

    Alternate Names:
    CHE1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:

  • TTD: Cholinesterase

    • Version: 2020.06.01

    Alternate Names:
    BCHE TTD Gene Abbreviation
    T99799 TTD Target ID

    Gene Info:

    Publications:

  • FDA: BCHE

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21